This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Torres-Narbona, M.
Right arrow Articles by Bouza, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Torres-Narbona, M.
Right arrow Articles by Bouza, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2007, p. 1126-1129, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01539-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Amphotericin B, Caspofungin, Itraconazole, Posaconazole, and Voriconazole against 45 Clinical Isolates of Zygomycetes: Comparison of CLSI M38-A, Sensititre YeastOne, and the Etest{triangledown}

Marta Torres-Narbona, Jesús Guinea,* José Martínez-Alarcón, Teresa Peláez, and Emilio Bouza

Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, University of Madrid, Spain

Received 11 December 2006/ Accepted 17 December 2006

We evaluated the activities of amphotericin B, itraconazole, voriconazole, caspofungin, and posaconazole against zygomycetes by CLSI M38-A, Etest and Sensititre. The most active drug was posaconazole, followed by amphotericin B and itraconazole. The correlation of the Etest and Sensititre with CLSI M38-A was moderate for posaconazole but poor for the others.

* Corresponding author. Mailing address: Servicio de Microbiología Clínica, Hospital Universitario Gregorio Marañón, Dr. Esquerdo, 46, 28007 Madrid, Spain. Phone: 34914265104. Fax: 34915044906. E-mail: jguineaortega{at}yahoo.es.

{triangledown} Published ahead of print on 28 December 2006.

Antimicrobial Agents and Chemotherapy, March 2007, p. 1126-1129, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01539-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Khan, Z. U., Ahmad, S., Brazda, A., Chandy, R. (2009). Mucor circinelloides as a Cause of Invasive Maxillofacial Zygomycosis: an Emerging Dimorphic Pathogen with Reduced Susceptibility to Posaconazole. J. Clin. Microbiol. 47: 1244-1248 [Abstract] [Full Text]  
  • Morris, M. I. (2009). Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 66: 225-236 [Abstract] [Full Text]  
  • Perkhofer, S., Locher, M., Cuenca-Estrella, M., Ruchel, R., Wurzner, R., Dierich, M. P., Lass-Florl, C. (2008). Posaconazole Enhances the Activity of Amphotericin B against Hyphae of Zygomycetes In Vitro. Antimicrob. Agents Chemother. 52: 2636-2638 [Abstract] [Full Text]  
  • Rogers, T. R. (2008). Treatment of zygomycosis: current and new options. J Antimicrob Chemother 61: i35-i40 [Abstract] [Full Text]  
  • Guembe, M., Guinea, J., Pelaez, T., Torres-Narbona, M., Bouza, E. (2007). Synergistic Effect of Posaconazole and Caspofungin against Clinical Zygomycetes. Antimicrob. Agents Chemother. 51: 3457-3458 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»